Alyeska Investment Group
MACK

Alyeska Investment Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Alyeska Investment Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-20,601
Closed -$1.09M – 376
2013
Q2 		$1.09M Buy
+20,601
New +$903K 0.05% 235

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's MACK Position: Q3 2013 in Review

Alyeska Investment Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2013, closing a stake of 20,601 shares — an estimated $1.09M sold.

Alyeska Investment Group first reported a position in MACK in Q2 2013 and held it in 1 quarter. The position peaked at $1.09M in Q2 2013. 95 funds tracked by Wall St. Rank hold MACK as of Q3 2013.

  • Alyeska Investment Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Alyeska Investment Group sold 20,601 Merrimack Pharmaceuticals, Inc. shares in Q3 2013, an estimated $1.09M.
  • Alyeska Investment Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Alyeska Investment Group's Merrimack Pharmaceuticals, Inc. position peaked at $1.09M in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2013.

Based on Alyeska Investment Group's 13F filing for Q3 2013, filed 14 Nov 2013.